natgillin/translations-raw huggingface dataset:
In the field of human medicinal products, the Agency, in addition to the actions mentioned above, will focus on the implementation of the initiatives that the EMEA/CHMP Think-Tank on innovative drug development has elaborated. 
Poleg zgoraj omenjenih dejavnosti se bo Agencija na področju zdravil za uporabo v humani medicini osredotočila na izvajanje pobud, ki jih je razvila ustvarjalna enota EMEA/CHMP za razvoj inovativnih zdravil.
Legal sector 
Sektor za pravne zadve
The Agency will also progress the validation of the EudraVigilance data-analysis system (EU telematics project). 
Agencija bo tudi nadaljevala validacijo sistema obdelave podatkov EudraVigilance (telematski projekt EU).
MANAGEMENT BOARD 
UPRAVNI ODBOR
Additional functionalities will be added to the database and known defects resolved in the course of 2008 (EU telematics project). 
V letu 2008 bodo podatkovni bazi dodane dodatne funkcionalnosti, in odpravljene bodo ugotovljene pomanjkljivosti (telematski projekt EU).
Taking this into account, and also considering the EU legislation aimed at improving the availability of medicinal products in children, the Agency will increase its supervision of the conduct and ethical standards of clinical trials performed outside the EU. 
Ob upoštevanju tega dejstva ter glede na zakonodajo EU, ki želi izboljšati dostopnost zdravil za otroke, bo Agencija povečala nadzor izvajanja ter etičnih standardov pri kliničnih preskušanjih zunaj EU.
Continue the contribution to pan-European efforts to facilitate innovation and research, and thus to increase availability of medicines, in particular through participation in the work of the Innovative Medicines Initiative for human medicines, the European Technology Platform for Global Animal Health for veterinary medicines, and the continued implementation of recommendations of the EMEA/CHMP Think-Tank Group on innovative drug development. 
Nadalje prispevati k vseevropskemu prizadevanju za spodbujanje inovacij in raziskav ter tako povečati dostopnost zdravil, zlasti s sodelovanjem pri delu pobude za inovativna zdravila za uporabo v humani medicini (Innovative Medicines Initiative), evropske tehnološke platforme za globalno zdravje živali (European Technology Platform for Global Animal Health) za zdravila za uporabo v veterinarski medicini ter z nadaljnjim izvajanjem priporočil ustvarjalne enote EMEA/CHMP za razvoj inovativnih zdravil;
The Agency provides financial incentives because such medicines might, for economic reasons, not otherwise be developed. 
Takih zdravil iz gospodarskih razlogov morda ne bi razvijali, zato Agencija prispeva finančne spodbude.
For matters relating to pharmacovigilance for 
Za zadeve v zvezi s farmakovigilanco za
Pharmacovigilance and post-authorisation safety and efficacy of medicines 
Farmakovigilanca ter varnost in učinkovitost zdravil po izdaji dovoljenja za promet
Contribute to earlier availability of medicines for human and veterinary use 
Prispevati k zgodnejši dostopnosti zdravil za uporabo v humani in veterinarski medicini
Promote the supervision of veterinary medicines once authorised, through effective and targeted pharmacovigilance, including further development and use of the EudraVigilance veterinary database for continuous surveillance, and establishment of the concept of risk-management plans as it applies to the veterinary context. 
Spodbujanje nadzora zdravil za uporabo v veterinarski medicini po izdaji dovoljenja za promet z učinkovito in ciljno farmakovigilanco, kar vključuje nadaljnji razvoj in uporabo veterinarske baze podatkov EudraVigilance za stalni nadzor, in uvedbo koncepta načrtov za obvladovanje tveganja v okviru veterinarske medicine.
The Agency plans to make further progress on parallel review of the development of paediatric medicines with this international partner. 
Agencija želi s svojim mednarodnim partnerjem doseči nadaljnji razvoj pri vzporednem ocenjevanju razvoja pediatričnih zdravil.
Expenditure 
Odhodki
European public- and animal-health activities 
1.4 Evropske dejavnosti na področju javnega zdravja in zdravja živali
For product quality defects and recalls see www.emea.europa.eu/inspections/defectinstruction.html for instructions and contact points 
Za pomanjkljivosti izdelkov in druge preklice pojdite na naslov www.emea.europa.eu/inspections/defectinstruction.html, ki vsebuje navodila in kontaktne osebe E-pošta: qdefect@emea.europa.eu
Pharmacovigilance and maintenance activities 
2.6 Farmakovigilanca in vzdrževalne dejavnosti
The Agency plans to streamline the implementation of legislative requirements regarding the review of profitability of such medicines after their authorisation, in the light of a new Commission guideline. 
V skladu z novimi smernicami Komisije namerava Agencija racionalizirati izvajanje zakonodajnih zahtev v zvezi z ocenjevanjem dobičkonosnosti takih zdravil po pridobitvi dovoljenja za promet.
Parallel-distribution notifications (Input) 
Obvestila o vzporedni distribuciji (Vhodni podatek)
To strengthen this trend and to facilitate the availability of medicines, the Agency will work with the Heads of Veterinary Medicines Agencies to implement new measures to provide support to companies considering applications for limited markets and/or for regional diseases. 
Da bi te smernice okrepili in omogočili lažjo dostopnost zdravil, bo Agencija sodelovala z vodji agencij za veterinarska zdravila, da se bodo izvedli novi ukrepi za pomoč podjetjem, ki se zanimajo za dovoljenja za omejene trge in/ali lokalne bolezni.
The EMEA will continue to be involved in the work of the ICH, VICH and Codex Alimentarius, will participate in international standardisation activities, and will further collaborate with the WHO, the World Organisation for Animal Health and other international organisations. 
EMEA bo še naprej vključena v delo ICH, VICH, Codexa Alimentariusa ter bo sodelovala pri mednarodnih dejavnostih na področju standardizacije.
Implement initiatives in cooperation with the Heads of Veterinary Medicines Agencies aimed at facilitating greater availability of veterinary medicines, particularly through measures to assist micro, small and medium-sized veterinary enterprises and companies seeking to authorise products for minor species and/or limited markets. 
Izvajati pobude v sodelovanju z vodji agencij za zdravila za uporabo v veterinarski medicini s ciljem, da se omogoči večja dostopnost zdravil za uporabo v veterinarski medicini, zlasti z ukrepi za pomoč mikro, malim in srednje velikim veterinarskim podjetjem in družbam, ki želijo pridobiti dovoljenje za promet z zdravili za manj pomembne vrste in/ali za omejene trge.
Continue to improve the safety-monitoring of medicines for human and veterinary use 
Nadalje izboljšati spremljanje varnosti zdravil za uporabo v humani in veterinarski medicini
Strengthen the European medicines network 
Okrepiti Evropsko mrežo zdravil
Post-authorisation activities 
2.5 Dejavnosti po izdaji dovoljenja
Sampling from the market in different countries is carried out by national inspectorates and testing is performed by official medicines-control laboratories coordinated by the European Directorate for the Quality of Medicines and HealthCare (EDQM). 
Vzorčenje s trgov v različnih državah opravljajo nacionalni inšpektorati, preskušanje pa izvajajo uradni laboratoriji za kontrolo
This will be the sixth year of implementation by the Agency, with national competent authorities, of the EU telematics programme. 
Leto 2008 bo šesto leto izvajanja programa EU telematskih projektov s strani Agencije v sodelovanju z nacionalnimi odgovornimi organi.
The Agency's Committee on Herbal Medicinal Products (HMPC) provides scientific opinions on questions relating to herbal medicines; establishes Community herbal monographs for traditional and well-established herbal medicinal products; establishes a draft list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products; provides opinions on herbal substances as needed; and evaluates referrals and arbitrations concerning traditional herbal medicinal products. 
Odbor za zdravila rastlinskega izvora (HMPC) pripravlja strokovna mnenja o vprašanjih v zvezi z zdravili rastlinskega izvora, oblikuje monografije rastlin Skupnosti za tradicionalna in dobro uveljavljena zdravila rastlinskega izvora ter pripravlja osnutek seznama snovi rastlinskega izvora, pripravkov in njihovih kombinacij za uporabo v tradicionalnih zdravilih rastlinskega izvora.
on the Internet at www.emea.europa.eu by e-mail request to info@emea.europa.eu by fax to (44-20) 74 18 86 70 by writing to: 
na internetu na naslovu www.emea.europa.eu na podlagi zahtevka, ki ga pošljete na elektronski naslov info@emea.europa.eu po faksu na št. (44-20) 7418 8670 pisno na naslov:
Temporary posts 
Začasna delovna mesta
For enquiries concerning PMF certificates 
Za vprašanja v zvezi s potrdili PMF
Applications for designation (input) Opinions on designation (output) 
Vloge za določitev (vhodni podatek) Mnenja o določitvah (izhodni podatek)
SME Office contact point: 
Kontaktna oseba Urada za mala in srednje velika podjetja:
The EMEA will work with the Heads of Veterinary Medicines Agencies to implement initiatives to be adopted by the EMEA Management Board aimed at facilitating greater availability of veterinary medicines through a set of measures to assist companies seeking to authorise products for minor species and/or limited markets. 
EMEA bo sodelovala z vodji agencij za veterinarska zdravila pri izvajanju pobud, ki jih bo sprejel upravni odbor EMEA, katerih namen bo omogočiti večjo dostopnost veterinarskih zdravil, z ukrepi, ki bodo nudili pomoč podjetjem, ki bodo želela pridobiti dovoljenje za promet z zdravili za manj pomembne vrste in/ali omejene trge.
Arbitration and Community referrals 
2.8 Arbitraža in napotitve Skupnosti
Scientific advice and follow-up requests Protocol assistance and follow-up requests 
Zahtevki za znanstveno svetovanje in spremljanje Zahtevki za pomoč pri protokolu in spremljanje
The EMEA issues plasma-master-file (PMF) and vaccine-antigen-master-file (VAMF) certificates of a medicinal product in conformity with the arrangements laid down by Community legislation. 
Agencija EMEA izdaja potrdila o glavnem dosjeju o plazmi (PMF) in glavnem dosjeju o antigenih cepiva (VAMF) v skladu z zakonodajo Skupnosti.
The Agency expects that the number of certificate requests will increase in 2008 by 
Agencija pričakuje, da se bo število prošenj za potrdila v letu 2008 povečalo za 20 %.
In order to complete the development of EudraVigilance Veterinary, the Agency's Management Board adopted the EudraVigilance Veterinary Action Plan. 
Upravni odbor Agencije je sprejel akcijski načrt veterinarskega sistema EudraVigilance (EudraVigilance Veterinary Action Plan), da bi dokončali razvoj veterinarskega sistema EudraVigilance.
A separate programme encompassing all information-management activities in the Agency will be launched to implement this objective. 
Za dosego tega cilja bo Agencija začela izvajati poseben program, ki bo obsegal vse dejavnosti, ki zadevajo upravljanje informacij v Agenciji.
Project management 
Projektno vodenje
Applications for initial evaluation (Input) 
Vloge za začetno oceno (Vhodni podatek)
This will be done through the implementation of the EudraVigilance Action Plan, which helps the European medicines network to improve the quality of data submitted to the database. 
Drugo področje dejavnosti bo zadevalo nenehne izboljšave podatkovne baze sistema EudraVigilance, kar bo Agenciji omogočilo izvajanje akcijskega načrta EudraVigilance, ki pomaga Evropski mreži zdravil izboljšati kakovost podatkov, posredovanih v podatkovno bazo.
ANNEXES 
Priloge
In preparation for the implementation of legislation on advanced-therapy medicinal products, the Agency will develop guidance in the fields of post-authorisation follow-up on efficacy, adverse reactions and risk-management of these products. 
Začetna obvestila skupaj izvajanje zakonodaje o zdravilih za napredne terapije razvila smernice za spremljanje učinkovitosti po izdaji dovoljenja za promet, neželenih učinkov ter obvladovanja tveganja pri teh zdravilih.
E-mail: certificate@emea.europa.eu authorised medicines for human or veterinary use 
Za vprašanja v zvezi z dovoljenji za zdravila E-pošta: certificate@emea.europa.eu za uporabo v humani medicini in zdravila
Out-of-hours telephone: (44) 78 80 55 06 97 
Telefon zunaj uradnih ur: (44)-7880 55 06 97
Martin HARVEY ALLCHURCH Direct telephone (44-20) 74 18 84 27 E-mail: press@emea.europa.eu 
Martin HARVEY ALLCHURCH Direktni telefon (44-20) 74 18 84 27 E-pošta: press@emea.europa.eu
Function group & Grade Permanent posts 
Funkcionalna skupina in stopnja
CVMP Committee for Medicinal Products for Veterinary Use 
CVMP Odbor za zdravila za uporabo v veterinarski medicini
Initial evaluation 
2.3 Začetna ocena
Establishment of maximum residue limits for veterinary medicines 
2.4 Določitev mejne vrednosti ostankov za zdravila za uporabo v veterinarski medicini
Occupied as per 
Zasedenost na dan
New applications for veterinary medicines (Input) 
Nove vloge za zdravila za uporabo v veterinarski medicini, prejete/predvidene (vhodni podatek)
This trend will be further strengthened as a consequence of the implementation of the paediatric legislation. 
Zaradi zakonodaje o pediatriji se bo te smernice še okrepile.
An improved tool that will help the Agency and its partners to rationalise the processing of pharmacovigilance information - the EudraVigilance Veterinary Data Warehouse (EU telematics project) - will be implemented in 2008. 
V letu 2008 bo Agencija uvedla izboljšano orodje telematskega projekta EU - skladišče veterinarskih podatkovni zbirk Eudravigilance (EudraVigilance Veterinary Data Warehouse) - ki bo njej in njenim partnerjem pomagalo racionalizirati obdelavo podatkov o farmakovigilanci.
Direct telephone: (44-20) 74 18 85 81 E-mail: vet-phv@emea.europa.eu 
Direktni telefon: (44-20) 74 18 85 81 E-pošta: vet-phv@emea.europa.eu
CHMP Committee for Medicinal Products for Human Use 
CHMP Odbor za zdravila za uporabo v humani medicini
Scientific-advice and protocol-assistance requests (Input) 
Zahtevki za znanstveno svetovanje in pomoč pri protokolu (Vhodni podatek)
As part of this initiative, the EMEA will finalise the development of its communication strategy and will consolidate the various communication tools into a communication ‘platform'. 
Kot del te pobude bo EMEA dokončala razvoj svoje komunikacijske strategije in združila različna komunikacijska orodja v komunikacijsko „platformo“, kar ji bo pomagalo zagotoviti, da bodo bolniki in zdravstveni delavci prejemali visokokakovostne, ciljne in pravočasne informacije.
This includes support to the implementation of the referral procedure, development and maintenance of the memory of regulatory and scientific agreements, and activities arising from the paediatric medicines regulation. 
Agencija bo še naprej podpirala koordinacijske skupine za postopek medsebojnega priznavanja in decentralizirani postopek (za zdravila za uporabo v humani in veterinarski medicini), kar vključuje pomoč pri izvajanju napotitvenega postopka, razvoj in vzdrževanje spomina regulativnih in znanstvenih dogovorov ter dejavnosti, ki izvirajo iz uredbe o zdravilih za uporabo v pediatriji.
Type-I variation applications Type-II variation applications Line-extension applications 
Vloge za spremembe tipa II
MEDICINES FOR HUMAN AND VETERINARY USE 
Zdravila za uporabo v humani in veterinarski medicini
A number of guidance documents on advanced-therapy medicinal products and new technologies will be developed in consultation with interested parties. 
Po posvetovanju z zainteresiranimi stranmi bo Agencija razvila številne smernice o zdravilih za napredne terapije in nove tehnologije.
Nonetheless, applications for MRLs for products classified by the CVMP as indicated for limited markets may be forthcoming in response to the assistance provided by the Agency for these types of products. 
Kot odgovor na pomoč, ki jo Agencija daje za taka zdravila, pa bodo verjetno vseeno prispele vloge za mejne vrednosti ostankov (MVO) za zdravila, ki jih CVMP opredeljuje kot namenjene za omejene trge.
One of the main activities in 2008 will be to prepare for the implementation of the project on the European Network of 
Ena glavnih dejavnosti v letu 2008 bo priprava na izvajanje projekta Evropske mreže centrov za farmakovigilanco in farmakoepidemiologijo.
COMP Committee for Orphan Medicinal Products 
Odbor za zdravila sirote
Press office 
Tiskovni urad Tiskovni predstavnik
Total grade AST Grand Total 
Stopnja AST skupaj Skupaj
VETERINARY MEDICINES AND INSPECTIONS 
ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI IN INŠPEKCIJSKI PREGLEDI
As such, the European medicines network is fundamental to the successful work of the Agency. 
Za izpolnitev svoje naloge javnega zdravja se Agencija opira na uporabo znanstvenih virov Evropske mreže zdravil, ki je tako osnovnega pomena za uspešno delo Agencije.
Silvia DOMINGO ROIGÉ Direct telephone: (44-20) 74 18 85 52 Fax: (44-20) 74 18 85 45 
Silvia DOMINGO ROIGÉ Direktni telefon: (44-20) 74 18 85 52 Faks: (44-20) 74 18 85 45
For enquiries concerning certificates for centrally 
izdanimi po centraliziranem postopku
HMPC Committee on Herbal Medicinal Products 
HMPC Odbor za zdravila rastlinskega izvora
Health authorities rely on centralised assessments to support marketing in their own countries, thus facilitating the availability of medicines and avoiding the need for costly and double assessment work. 
Tako se omogoči dostopnost zdravil ter izogne potrebi po dragem in dvojnem ocenjevanju.
Designation of orphan medicinal products 
Določitev zdravil sirot
Applications for new medicinal products Generic applications 
Vloge za nova zdravila Vloge za generična zdravila
Medicines for children 
3.1 Zdravila za otroke
Scientific advice and protocol assistance 
2.2 Znanstveno svetovanje in pomoč pri protokolu
Direct telephone: (44-20) 74 18 85 75/84 63 Fax: (44-20) 75 23 70 40 
Direktni telefon: (44-20) 74 18 85 75/84 63 Faks: (44-20) 75 23 70 40
Safety of veterinary medicines 
Varnost zdravil za uporabo v veterinarski medicini
Scientific-advice requests (Input) 
Zahtevki za znanstveno svetovanje, prejeti/predvideni (Vhodni podatek)
GMP, GCP, GLP and pharmacovigilance inspections 
2.12 Inšpekcijski pregledi dobre proizvodne prakse, dobre klinične prakse, dobre laboratorijske prakse in farmakovigilance
E-mail: smeoffice@emea.europa.eu 
E-pošta: smeoffice@emea.europa.eu
E-mail: VAMF@emea.europa.eu 
E-pošta: VAMF@emea.europa.eu
Direct telephone: (44-20) 74 18 86 98 Fax: (44-20) 74 18 85 45 
Direktni telefon: (44-20) 74 18 8698 Faks: (44-20) 74 18 85 45
E-mail: PMF@emea.europa.eu 
E-pošta: PMF@emea.europa.eu
EEA and non-EEA ADR reports transmitted to the EMEA for centralised authorisation procedure (CAP) and non-CAP products 
Dejansko in ocenjeno število poročil o neželenih učinkih zdravil iz EGP in zunaj EGP, poslanih EMEA
Orphan medicinal products for human use 
2.1 Zdravila sirote za uporabo v humani medicini
medicinal products for human use 
Zdravila za uporabo v humani medicini
medicinal products for veterinary use 
zdravila za uporabo v veterinarski medicini
The development of the electronic Application Form (eAF) for human medicinal products will be completed in 2008 (EU telematics project); A system to support the use of the eAF standard will also be developed and maintained by the Agency in connection with the centralised procedure. 
V letu 2008 bo dokončan razvoj elektronskega obrazca vloge (eAF) za zdravila v humani medicini (telematski projekt EU).
ref.: EMEA/MB/556125/2007 
EMEA/172874/2008
Applications received (Input) 
Vloge prejete/predvidene (vhodni podatek)
Direct telephone: (44-20) 75 23 71 07 Fax: (44-20) 74 18 85 95 
Direktni telefon: (44-20) 75 23 71 07
European medicines network 
1.1 Evropska mreža zdravil
Contribution from EEA Community programmes Other 
Programi Skupnosti
Veterinary marketing authorisation procedures 
Postopki za izdajo dovoljenja za promet z zdravili v veterini
TOTAL EXPENDITURE 
ODHODKI SKUPAJ
Annex 4 EMEA contact points Pharmacovigilance and product-quality-defect reporting 
Priloga 4 Kontaktne osebe agencije EMEA
Centres for Pharmacovigilance and Pharmacoepidemiology (ENCePP). 
pharmacovigilance@emea.europa.eu Za zadeve v zvezi s farmakovigilanco za
applications 
Pristojbine
Currently available data are described in section 4.3, 4.4, 4.8, 5.1 and 5.2. 
Trenutno dostopni podatki so opisani v poglavjih 4.3, 4.4, 4.8, 5.1 in 5.2.
THE FOLLOWING INFORMATION IS INTENDED FOR HEALTHCARE PROFESSIONALS ONLY 
NASLEDNJE INFORMACIJE SO NAMENJENE IZKLJUČNO ZDRAVSTVENEMIM DELAVCEM:
Your doctor will advise on benefits and risks of this medicine. 
Vaš zdravnik vas bo poučil o koristih in tveganjih, povezanih s tem zdravilom.
The long-term benefits and risks of this medicine in children and adolescents are not yet clear. 
Dolgoročne koristi in tveganja za otroke in mladostnike v zvezi s tem zdravilom še niso jasni.
Cardioxane is also contraindicated in the following circumstances: 
Zdravilo Cardioxane je kontraindicirano tudi v naslednjih primerih:
This product information is the outcome of the referral procedure to which this Commission decision relates. 
Te informacije o zdravilu so rezultat napotitvenega postopka na katerega se nanaša odločitev Evropske komisije.
What you need to know before you are given Cardioxane You must not be given Cardioxane 
Kaj morate vedeti, preden boste prejeli zdravilo Cardioxane
Annex III Amendments to the relevant sections of the Product information 
Priloga III Dopolnitve ustreznih poglavij informacij o zdravilu
− If you are under 18 years old and your planned dose of anthracycline is considered low - talk to your doctor about this. 
− Če ste mlajši od 18 let in načrtovani odmerek antraciklina velja za nizkega - o tem se posvetujte s svojim zdravnikom.
The valid summary of product characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure with the following amendments (insertion, replacement or deletion of the text as appropriate) to reflect the agreed wording as provided below: A. Summary of Product Characteristics 
Veljavni povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo so zadnje različice, dogovorjene v postopku skupine za usklajevanje CMDh z naslednjimi dopolnili (vstavitev, zamenjava ali brisanje besedila, kot je ustrezno), da odražajo dogovorjeno besedilo, kot je navedeno v nadaljevanju:
The safety and efficacy of Cardioxane in children aged 0 to 18 years have not been established. 
Varnost in učinkovitost zdravila Cardioxane pri otrocih, starih 0 do 18 let, še nista dokazani.
The product information may be subsequently updated by the Member State competent authorities, in liaison with the Reference Member State, as appropriate, in accordance with the procedures laid down in Chapter 4 of Title III of Directive 2001/83/EC. 
Informacije o zdravilu lahko pristojni organi držav članic naknadno posodobijo ob sodelovanju referenčne države članice, če je to potrebno, v skladu s postopki, določenimi v 4.
Children and adolescents up to 18 years of age (see sections 4.4 and 4.8). 
4.3 Kontraindikacije Otroci in mladostniki do 18 let (glejte poglavji 4.4. in 4.8.
Cardioxane is contraindicated in children and adolescents up aged 0 to 18 years of age who are planned to receive a cumulative dose of less than 300 mg/m2 of doxorubicin or the equivalent cumulative dose of another anthracycline. 
Cardioxane je kontraindiciran pri otrocihin mladostnikih, starih od 0 do 18 let starosti, pri katerih se načrtuje prejemanje kumulativnega odmerka doksorubicina manjšega kot 300 mg/m2 ali enakovrednega kumulativnega odmerka drugega antraciklina.
Cardioxane is contraindicated in children and adolescents up to 18 years of age (see section 4.3). 
Cardioxane je kontraindiciran pri otrocih in mladostnikih, starih do 18 let (glejte poglavje 4.3).
4.3 Contraindications 
A. Povzetek glavnih značilnosti zdravila
If you are allergic to: 
če ste alergični na:
12 months 
12 mesecev
Date of first authorisation: 12 December 2018 
Datum prve odobritve: 12. december 2018
Not known (cannot be estimated from the available data): 
Neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov):